Core Viewpoint - PolyPid Ltd. is set to report its first quarter 2025 financial results and operational highlights on May 14, 2025, with a conference call scheduled for 8:30 AM Eastern Time to discuss these results and provide business updates [1]. Company Overview - PolyPid Ltd. is a late-stage biopharma company focused on improving surgical outcomes through its proprietary PLEX technology, which allows for controlled, prolonged-release of therapeutics [4]. - The lead product candidate, D-PLEX100, is currently in Phase 3 clinical trials aimed at preventing abdominal colorectal surgical site infections [4]. - The company is also in preclinical stages testing OncoPLEX for treating solid tumors, starting with glioblastoma [4]. Conference Call Details - The conference call will take place on May 14, 2025, at 8:30 AM Eastern Time, and participants are encouraged to register at least 5 minutes prior to the call [2][3]. - For those not asking questions, listening via the webcast is recommended [2].

Group 1 - PolyPid Ltd. is a late-stage biopharma company focused on improving surgical outcomes through innovative drug delivery systems [2] - The company utilizes its proprietary PLEX technology for controlled, prolonged-release therapeutics, allowing for precise drug delivery over extended periods [2] - PolyPid's lead product candidate, D-PLEX100, is currently in Phase 3 clinical trials aimed at preventing abdominal colorectal surgical site infections [2] Group 2 - The company is also in preclinical stages testing OncoPLEX for the treatment of solid tumors, starting with glioblastoma [2] - PolyPid management will participate in a fireside chat at The Citizens Life Sciences Conference in New York on May 7, 2025 [1] - Investors interested in meeting with PolyPid during the conference can contact their Citizens JMP representative [1]